Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria

International Journal of Antimicrobial Agents

Volumn 40, Issue 4, 2012, Pages 313-322

  Asín, Eduardo ^a   Isla, Arantxazu ^a   Canut, Andrés ^b   Rodríguez Gascón, Alicia ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL TXAGORRITXU   (Spain)

Author keywords

Enterococci; Minimum inhibitory concentration (MIC); Monte Carlo simulation; Pharmacokinetics pharmacodynamics; Staphylococci; Streptococci

Indexed keywords

AMOXICILLIN; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CLOXACILLIN; DAPTOMYCIN; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG TREATMENT FAILURE; GRAM POSITIVE BACTERIUM; MATHEMATICAL MODEL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACOKINETIC PHARMACODYNAMIC MODEL; PREDICTION; PRIORITY JOURNAL;

ADULT; ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD;

EID: 84866036971     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.06.005     Document Type: Article

References (30)

1. S.K. Olofsson, and O. Cars Optimizing drug exposure to minimize selection of antibiotic resistance Clin Infect Dis 45 Suppl. 2 2007 S129 S136
2. J.S. Bradley, M.N. Dudley, and G.L. Drusano Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation Pediatr Infect Dis J 22 2003 982 992
3. A. Canut, A. Isla, C. Betriu, and A.R. Gascón Pharmacokinetic- pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries Eur J Clin Microbiol Infect Dis 2012 10.1007/s10096-012-1560-7 [Epub ahead of print]
4. P.G. Ambrose Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the Society of Infectious Diseases Pharmacists Pharmacotherapy 26 2006 129 134
5. P.G. Ambrose Antimicrobial susceptibility breakpoints: PK-PD and susceptibility breakpoints Treat Respir Med 4 Suppl. 1 2005 5 11
6. C.A. DeRyke, J.L. Kuti, and D.P. Nicolau Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment Diagn Microbiol Infect Dis 58 2007 337 344
7. M.P. Weinstein, K.P. Klugman, and R.N. Jones Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance Clin Infect Dis 48 2009 1596 1600
8. M. Rybak, B. Lomaestro, J.C. Rotschafer, R. Moellering, W. Craig, and M. Billeter Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 2009 82 98
9. D. Staniforth, D. Jackson, R. Horton, and B. Davies Parenteral augmentin: pharmacokinetics Int J Clin Pharmacol Ther Toxicol 22 1984 430 434
10. E.H. Nauta, and H. Mattie Pharmacokinetics of flucloxacillin and cloxacillin in healthy subjects and patients on chronic intermittent haemodialysis Br J Clin Pharmacol 2 1975 111 121
11. M.K. Kim, B. Capitano, H.M. Mattoes, D. Xuan, R. Quintiliani, and C.H. Nightingale Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam Pharmacotherapy 22 2002 569 577
12. D.E. Nix, J.H. Wilton, J. Hyatt, J. Thomas, L.C. Strenkoski-Nix, and A. Forrest Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers Antimicrob Agents Chemother 41 1997 1108 1114
13. S.V. Bhat, A.Y. Peleg, T.P. Lodise Jr., K.A. Shutt, B. Capitano, and B.A. Potoski Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms Antimicrob Agents Chemother 51 2007 4390 4395
14. L.A. Bauer, D.J. Black, and J.S. Lill Vancomycin dosing in morbidly obese patients Eur J Clin Pharmacol 54 1998 621 625
15. B.H. Dvorchik, D. Brazier, M.F. DeBruin, and R.D. Arbeit Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects Antimicrob Agents Chemother 47 2003 1318 1323
16. M. Benvenuto, D.P. Benziger, S. Yankelev, and G. Vigliani Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers Antimicrob Agents Chemother 50 2006 3245 3249
17. G. Muralidharan, M. Micalizzi, J. Speth, D. Raible, and S. Troy Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects Antimicrob Agents Chemother 49 2005 220 229
18. A.P. MacGowan Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections J Antimicrob Chemother 51 Suppl. 2 2003 ii17 ii25
19. J.W. Mouton, M.N. Dudley, O. Cars, H. Derendorf, and G.L. Drusano Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs Int J Antimicrob Agents 19 2002 355 358
20. R. Benko, M. Matuz, P. Doro, Z. Peto, A. Molnar, and E. Hajdu Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia Int J Antimicrob Agents 30 2007 162 168
21. D. Maglio, J.L. Kuti, and D.P. Nicolau Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program Clin Ther 27 2005 1032 1042
22. C.R. Frei, N.P. Wiederhold, and D.S. Burgess Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation J Antimicrob Chemother 61 2008 621 628
23. P. Liu, M. Müller, and H. Derendorf Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations Int J Antimicrob Agents 19 2002 285 290
24. J.A. Roberts, C.M.J. Kirkpatrick, and J. Lipman Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients J Antimicrob Chemother 66 2011 227 231
25. J. Turnidge, and D.L. Paterson Setting and revising antibacterial susceptibility breakpoints Clin Microbiol Rev 20 2007 391 408
26. J.C. Gallagher, M.E. Perez, E.A. Marino, L.G. LoCastro, L.A. Abrardo, and C. MacDougall Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients Pharmacotherapy 29 2009 792 799
27. D.P. Webster, S. Griffiths, and I.C. Bowler Failure of linezolid therapy for post-neurosurgical meningitis due to Enterococcus faecium J Antimicrob Chemother 63 2009 622 623
28. F.H. Saner, M. Heuer, P. Rath, J. Gensicke, A. Radtke, and N. Drühe Successful salvage therapy with tigecycline after linezolid failure in a liver transplant recipient with MRSA pneumonia Liver Transpl 12 2006 1689 1692
29. F. Pea, and P. Viale The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 42 2006 1764 1771
30. P.G. Ambrose, S.M. Bhavnani, C.M. Rubino, A. Louie, T. Gumbo, and A. Forrest Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore Clin Infect Dis 44 2007 79 86